Related Experiment Videos
[Pulmonary complications after bone marrow transplantation]
M Giacchino1, A Busca, R Miniero
1Istituto Discipline Pediatriche, Clinica Pediatrica II, Torino.
Abstract:
Pulmonary toxicity occurs in approximately 10 to 50% of patients undergoing bone marrow transplantation (BMT). Bacterial pneumonia very commonly affects patients within the first 6 months post-BMT. Etiologic factors include neutropenia and the presence of graft-versus-host disease (GVHD). Pulmonary fungal infections, due to candida and aspergillus, may develop in 16% of patients receiving BMT, with a high mortality rate, being about 80%. A prolonged neutropenia as well as GVHD and associated immunosuppressive treatments are important factors in predisposing a patient to develop fungal pneumonitis. Interstitial pneumonitis occurs in 10-40% of patients; herpes viruses are the most commonly documented cause, with cytomegalovirus (CMV) being the most common pathogen. No causative organism is identified in up to 60% of the cases. It is likely that some of these cases may result from drug or radiation toxicity. Lung shielding and fractionation of the dose have decreased the incidence of interstitial pneumonitis to less than 5%. Patients with GVHD are predisposed to lung infections because of the immunosuppression that accompanies GVHD and its treatment. In addition, GVHD itself appears to have a direct effect on pulmonary epithelium. Cultural and serologic studies as well as radiographic investigations and other diagnostic procedures (ie bronchoalveolar lavage) are needed for appropriate management of pulmonary complications.
Insights
Bone marrow transplantation (BMT) patients face significant pulmonary risks, including bacterial, fungal, and viral pneumonitis. Early diagnosis and management are crucial for improving outcomes in these vulnerable individuals.
Area of Science:
- Hematology
- Oncology
- Infectious Diseases
Context:
- Pulmonary complications are frequent in bone marrow transplantation (BMT) recipients, affecting 10-50% of patients.
- Bacterial pneumonia is common within 6 months post-BMT, linked to neutropenia and graft-versus-host disease (GVHD).
- Fungal infections (Candida, Aspergillus) have high mortality (80%) and are associated with prolonged neutropenia and immunosuppression.
Purpose:
- To review the spectrum of pulmonary complications following BMT.
- To identify key risk factors and pathogens associated with post-BMT lung injury.
- To emphasize the need for prompt diagnosis and management of pulmonary issues.
Summary:
- Interstitial pneumonitis occurs in 10-40% of BMT patients, often caused by herpes viruses like cytomegalovirus (CMV).
- In up to 60% of cases, the causative agent remains unidentified, potentially due to drug or radiation toxicity.
- GVHD and its treatments increase susceptibility to lung infections, with GVHD possibly directly affecting lung epithelium.
Impact:
- Improved understanding of pulmonary toxicity post-BMT can guide preventative strategies.
- Diagnostic procedures like bronchoalveolar lavage are essential for targeted treatment.
- Reduced incidence of interstitial pneumonitis has been achieved through radiation techniques like lung shielding and dose fractionation.